Halozyme Therapeutics, Inc. (FRA:RV7)
Germany
· Delayed Price · Currency is EUR 55.20
-1.00 (-1.78%)
At close: Dec 4, 2025
Revenue by Geography
Fiscal year is January - December.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2013 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2013 - 2020 |
| United States Revenue | - | 690.46M |
Log In |
Log In |
Log In | Upgrade
|
| Switzerland Revenue | - | 212.39M |
Log In |
Log In |
Log In | Upgrade
|
| Belgium Revenue | - | 84.01M |
Log In |
Log In |
Log In | Upgrade
|
| Japan Revenue | - | 18.94M |
Log In |
Log In |
Log In | Upgrade
|
| Ireland Revenue | - | - |
Log In |
Log In |
Log In | Upgrade
|
| All Other Foreign Countries Revenue (Pre-FY2023) | - | - |
Log In |
Log In |
Log In | Upgrade
|
| All Other Foreign Countries Revenue (Post-FY2022) | - | 9.53M |
Log In |
Log In |
Log In | Upgrade
|
| Revenue (Other) | 1.24B | - |
Log In |
Log In |
Log In | Upgrade
|
| Revenue (Total) | 1.24B | 1.02B |
Log In |
Log In |
Log In | Upgrade
|
Revenue
Fiscal year is January - December.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2013 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2013 - 2020 |
| Royalties Revenue | 780.29M | 570.99M |
Log In |
Log In |
Log In | Upgrade
|
| Sales of Proprietary Products | 182.34M | 166.62M |
Log In |
Log In |
Log In | Upgrade
|
| Sales of Bulk rHuPH20 | 102.48M | 86.33M |
Log In |
Log In |
Log In | Upgrade
|
| Sales of Device Partnered Products | 48.32M | 50.54M |
Log In |
Log In |
Log In | Upgrade
|
| Total Net Product Sales | 333.14M | 303.49M |
Log In |
Log In |
Log In | Upgrade
|
| Revenue Under Collaborative Agreements | 129.42M | 140.84M |
Log In |
Log In |
Log In | Upgrade
|
| Revenue (Total) | 1.24B | 1.02B |
Log In |
Log In |
Log In | Upgrade
|